Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

June 5, 2023

Study Completion Date

June 5, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

AMG 994

Administered as an intravenous (IV) infusion.

DRUG

AMG 404

Administered as an intravenous (IV) infusion.

Trial Locations (17)

3168

Monash Medical Centre, Clayton

6009

Linear Clinical Research Limited, Nedlands

9000

Universitair Ziekenhuis Gent, Ghent

37203

Sarah Cannon Research Institute, Nashville

44106

University Hospitals Cleveland Medical Center, Cleveland

48202

Henry Ford Hospital, Henry Ford Health Systems, Detroit

69008

Centre Leon Berard, Lyon

77030

University of Texas MD Anderson Cancer Center, Houston

89081

Universitatsklinikum Ulm, Ulm

91010

City of Hope National Medical Center, Duarte

97078

Universitätsklinikum Würzburg, Würzburg

M5G 2M9

Princess Margaret Cancer Centre, Toronto

277-8577

National Cancer Center Hospital East, Kashiwa-shi

791-0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

02-781

Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw

08035

Hospital Universitari Vall d Hebron, Barcelona

W1T 7HA

University College London Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY